Moderna reports surprise profit on higher-than-expected COVID vaccine sales
Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...
Cautious Outlook on Moderna: Declining Vaccine Demand and Strategic Challenges Prompt Sell Rating
Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...
Moderna posts surprise profit as Covid vaccine sales impress, cost cuts take hold
Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last ...
Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn
Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...
FiercePharma4d
Moderna disappoints in RSV debut, squares up with Pfizer in COVID-19 vaccine sales
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...
Moderna Stock Gains on Better-Than-Expected Covid-19 Vaccine Sales
Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed ...
Canada approves Moderna's RSV vaccine for adults aged 60 and older
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
Moderna, Pfizer or Novavax? How the three Covid-19 vaccines differ according to Yale Medicine
In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...
BioSpace4d
Moderna Gets Better-Than-Expected Q3 COVID-19 Vaccine Sales, but RSV Shot Disappoints
While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...
KSL12h
FDA lifts clinical hold on Novavax's combo COVID-flu shot
The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its ...
Moderna posts surprise profit as COVID vaccine sales exceed expectations
Moderna reported a surprising third-quarter profit on Thursday, driven by cost reductions and stronger-than-expected sales of ...
Reuters4d
Moderna reports surprise profit on higher-than-expected COVID vaccine sales
Shares up nearly 5% to $54.22 in early trading Spikevax COVID vaccine sales reached $1.8 billion, beating expectations Moderna expects lower COVID vaccine sales this year compared to 2023 $10 ...